We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Magnetically Navigable Microparticles Enable Targeted Drug Delivery

By HospiMedica International staff writers
Posted on 01 May 2025

Abdominal aortic aneurysms (AAA) can be life-threatening if not treated and result in nearly 10,000 deaths annually. More...

Researchers working to improve treatments for AAA could now make it possible for doctors to direct life-saving therapies through the body using only a magnet.

An interdisciplinary team at the University of Pittsburgh’s Swanson School of Engineering (Pittsburgh, PA, USA) has developed silk iron microparticles (SIMPs)—tiny, magnetic, and biodegradable carriers designed to precisely deliver drugs and treatments to targeted sites in the body, such as aneurysms or tumors. By enabling early-stage, noninvasive delivery of regenerative therapies via extracellular vesicles—membrane capsules that facilitate intercellular communication—the researchers aim to reduce the need for surgical interventions in treating AAA. The team’s goal was to find the most noninvasive method for delivering extracellular vesicles directly to the site of an AAA. They envisioned injecting extracellular vesicles onto a carrier and guiding the carrier to the aortic wall, using magnetic attraction.

The magnetic nanoparticles developed by the team are approximately one-hundred-thousandth the width of a human hair. At this minuscule scale, nanomaterials can be engineered to exhibit unique properties, such as magnetic responsiveness. While magnetically guided materials have been used in various medical applications, the team’s innovative approach involved chemically binding the magnetic nanoparticles to silk—a biocompatible material approved by the FDA—using the compound glutathione. This research, published in ACS Applied Materials & Interfaces, opens up numerous possibilities for future applications, ranging from targeted cancer therapies to regenerative treatments for cardiovascular diseases. With the ability to magnetically guide the particles, the next step is to load them with therapeutic agents. At the nanoscale, these findings also allow the team to further refine the particles’ molecular structure and control their drug release rates, enhancing their potential for biomedical use.

“With this paper, we’re showing that we can create an empty carrier that can be magnetically moved,” said Pitt alumna Ande Marini (BioE PhD ‘25), now a postdoctoral scholar in cardiothoracic surgery at Stanford University. “The next step is figuring out what kind of cargo we can load—regenerative factors, drugs, or other materials people want to magnetically localize. Whether it’s delivering cancer drugs with fewer side effects or slowing down tissue degradation in aneurysms, this technology has broad potential for regenerative medicine.”


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
12-Channel ECG
CM1200B
New
IV Therapy Cart
Avalo I.V Therapy Cart
New
ow Frequency Pulse Massager
ET10 L
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.